Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade.

Article Details

Citation

Copy to clipboard

Briani C, Cagnin A, Chierichetti F, Tiberio M, Battistin L, Pizzolato G

Thiethylperazine-induced parkinsonism: in vivo demonstration of dopamine D2 receptors blockade.

Eur J Neurol. 2004 Oct;11(10):709-10.

PubMed ID

15469457 [ View in PubMed

]

Abstract

Thiethylperazine (Torecan) is a piperazine phenothiazine employed to relieve vertigo. Its use may be associated with extrapyramidal side effects (dystonia, akathisia, tardive dyskinesia) (Sulkava, 1984), but parkinsonism has rarely been described. We describe a woman who, 1 month after the onset of thiethylperazine treatment, developed parkinsonism that disappeared 2 months after withdrawal of the drug. However, cerebral single-photon emission computed tomography (SPECT) with the dopamine (DA) D2 receptors ligand 123I-iodobenzamide (123I-IBZM) revealed a persistent reduced DA D2 receptors activity (by 45%) in the basal ganglia (BG), which may be clinically not effective.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Thiethylperazine	Dopamine D2 receptor	Protein	Humans	Unknown	Antagonist	Details